OPSYON

Developing innovative immunotherapeutics for better and safer #cancer treatment
#ImmunoOncology

[OPSYON @OPSYON_CD47]

See how our OPS-121 antibody-fusion re-activates immune cells against cancer. Within minutes of OPS-121 addition, #macrophages actively search and eat through #phagocytosis AML-related cancer cells. @NanoLiveLtd

#immunooncology

[OPSYON @OPSYON_CD47]

The Opsyon team is dedicated to #CloseTheCareGap
#WorldCancerDay2022
#immunooncology

[OPSYON @OPSYON_CD47]

Opsyon will attend and is a pitcher! at the 10th edition of BioFit, 7th-9th December 2021. Do not miss our Pitch on Thursday, December 9th at 9.00
#BioFIT2021 @BIOFIT_EVENT

[OPSYON @OPSYON_CD47]

OPSYON is presenting at #BIOEurope! Our presentation is already available on demand, and can be viewed throughout the whole conference. Login now to watch us! https://t.co/UgBzgudnZp

[OPSYON @OPSYON_CD47]

To all participants: see you at the #BES2021! Do not miss our pitch tomorrow!

[BioM Biotech Cluster Development @BioM_Munich]

🚀 Let's get started today! Be there at the BioEntrepreneurship Summit 2021! We hardly can't wait and are looking forward to 3 days of great speakers and exciting discussions!
See you there!
▶️https://t.co/2yO94zfcIq

[OPSYON @OPSYON_CD47]

OPSYON is attending #BIOEurope! Join us at the digital event, October 25–28, 2021 to request a partnering meeting. https://t.co/UgBzgudnZp

[OPSYON @OPSYON_CD47]

Thank you for the opportunity to pitch yesterday, and to all the participants as well!

[HTGF @HTGF]

Another five #startups pitched their innovative ideas to renowned investors at the LIFE SCIENCE PITCH DAY.💯Great pitches by: RecTec, @OPSYON_CD47, Invasight, Riana Therapeutics and Dimericon. #HTGF #LifeScience #PitchDay @Bayer, @BoehringerDE, IZB

[OPSYON @OPSYON_CD47]

Congrats to Siret for her publication on multifunctional antibodies targeting AML
#Immunotherapy

[hopfnerlab @hopfnerlab]

Towards promising therapeutic interventions to treat Acute Myeloid Leukaemia (AML): collaborating with the @subklewe group, we show preferential targeting of CD123+ CD47+ AML cells with SIRPα-αCD123 fusion antibodies.

https://t.co/oPii6R8qqp

[OPSYON @OPSYON_CD47]

We are looking forward to an exiting 6th Munich Life Science Pitch Day!

[HTGF @HTGF]

📢 The 6th Munich Life Science Pitch Day will take place tomorrow. Together with IZB - Innovation and Startup Center for Biotechnology, @Bayer, @BoehringerDE and renowned investors, we are looking forward to 10 pitch sessions ⬇

[OPSYON @OPSYON_CD47]

Follow new and exciting OPSYON's updates on our official LinkedIn page:
https://t.co/WSSz6FFC36

[OPSYON @OPSYON_CD47]

Our website is now launched!
https://t.co/4XWsMxfZTx

#websitelaunch

[Gene Center Munich @GeneCenter_LMU]

Great success for OPSYON! Congratulations!🥳🥳
OPSYON is a spin-off from the @hopfnerlab in close collaboration with the @subklewe lab. OPSYON develops innovative immunotherapeutics for better and safer cancer treatment

[BioM Biotech Cluster Development @BioM_Munich]

🚀Hooray!! Again a #biotech startup wins a @BayStartUp businessplan award! Congrats to @OPSYON_CD47!
https://t.co/QJsCG1RDcS

[OPSYON @OPSYON_CD47]

WE WON! Opsyon is the winner of the Munich Business Plan Competition 2021! Great Team! Great Success!
Congrats to all the finalists @BayStartUp
https://t.co/GzyOmQ77V2

#immunooncology

[BayStartUP @BayStartUp]

Die Siegerteams im Münchener Businessplan Wettbewerb 2021 stehen fest! #Opsyon, @divizend und @sewts_GmbH stehen auf dem Treppchen. Alle Infos: https://t.co/Y86BD8LaTn #biotech #fintech #robotics #MBPW

[Nanolive @NanoLiveLtd]

What if we could make our immune system strong enough to defeat #cancer?
@OPSYON_CD47, a spin-off from the @hopfnerlab of Prof. Dr. Karl-Peter Hopfner (@LMU_Muenchen, Germany), specializes in developing #antibody based therapeutics to this aim.
1/2

[OPSYON @OPSYON_CD47]

We´re excited to attend #ASH19 in Orlando #OCCC. We look forward to many interesting talks and discussions. Come and meet Nadja at Poster 2544 Session 604 on Sunday.

[OPSYON @OPSYON_CD47]

Opsyon opens up a postdoc position in the field of therapeutic antibody development. We are looking forward to your application.
https://t.co/slgwjDtd8J

[OPSYON @OPSYON_CD47]

#BIOEurope has just started and we are so excited to be here. Looking forward to enlarging our network and meeting many of you in Hamburg. 🤝

[OPSYON @OPSYON_CD47]

It was a great experience to meet more than 70 Exist-teams at the 20. Gründergespräch in Berlin. #ProjektträgerJülich #BMBF_Bund #BMWi_Bund #Exist #Forschungstransfer